Cincinnati, OH, United States of America

Kombo Flore N'guessan

This inventor holds 1 USPTO granted patent. Top assignee: University of Cincinnati. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kombo Flore N'guessan. Retrieved from https://idiyas.com/inventor/kombo-flore-n-guessan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kombo Flore N'guessan: Innovator in Cancer Treatment

Introduction

Kombo Flore N'guessan is a notable inventor based in Cincinnati, OH (US). He has made significant contributions to the field of cancer treatment through his innovative research and development.

Latest Patents

N'guessan holds a patent titled "Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles Against Pancreatic Cancer." This patent reflects his commitment to improving therapeutic strategies for one of the most challenging types of cancer.

Career Highlights

He is affiliated with the University of Cincinnati, where he continues to advance his research in cancer therapies. His work is characterized by a focus on combining existing treatments with novel delivery systems to enhance efficacy.

Collaborations

N'guessan collaborates with Xiaoyang Qi, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Kombo Flore N'guessan exemplifies the spirit of innovation in the medical field, particularly in the fight against pancreatic cancer. His contributions through patents and research are paving the way for more effective treatments.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…